{"id":"aczone-gel-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Oiliness/greasiness at application site"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Dryness"},{"rate":null,"effect":"Peeling"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dapsone is a sulfone antibiotic that exhibits both bacteriostatic activity against Cutibacterium acnes and direct anti-inflammatory effects by suppressing neutrophil function and reducing inflammatory mediators. When applied topically as a 5% gel, it penetrates the skin to reduce acne-related inflammation and bacterial load while minimizing systemic absorption.","oneSentence":"Dapsone reduces inflammation and bacterial colonization in acne lesions through its antimicrobial and anti-inflammatory properties.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:12.291Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT05926869","phase":"PHASE2","title":"Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2022-08-01","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT05899699","phase":"PHASE2","title":"Effect of New Topical Preparation for Treatment of Acne Vulgaris","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-06-05","conditions":"Acne Vulgaris","enrollment":20},{"nctId":"NCT01773122","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-01-21","conditions":"Acne Vulgaris","enrollment":77},{"nctId":"NCT01115244","phase":"PHASE4","title":"Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2010-07","conditions":"Dermatitis Herpetiformis","enrollment":1},{"nctId":"NCT00964366","phase":"PHASE4","title":"Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":53},{"nctId":"NCT02929719","phase":"PHASE1","title":"Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2014-04","conditions":"Acne Vulgaris","enrollment":1134},{"nctId":"NCT01931150","phase":"PHASE3","title":"Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-08","conditions":"Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT02865005","phase":"PHASE3","title":"Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Seegpharm S.A.","startDate":"2016-02","conditions":"Acne Vulgaris","enrollment":2361},{"nctId":"NCT01885910","phase":"PHASE4","title":"Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2013-07","conditions":"Acne Vulgaris","enrollment":32},{"nctId":"NCT01785836","phase":"PHASE1","title":"An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2013-03","conditions":"Acne Vulgaris","enrollment":""},{"nctId":"NCT01425320","phase":"PHASE1","title":"Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2013-01","conditions":"Acne Vulgaris","enrollment":""},{"nctId":"NCT01231334","phase":"PHASE4","title":"A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-08","conditions":"Acne Vulgaris","enrollment":286},{"nctId":"NCT01313728","phase":"PHASE4","title":"A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2010-12","conditions":"Acne Vulgaris","enrollment":26},{"nctId":"NCT00834210","phase":"PHASE4","title":"Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":171},{"nctId":"NCT00835198","phase":"PHASE4","title":"Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":163},{"nctId":"NCT00243542","phase":"PHASE4","title":"Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-11","conditions":"Acne Vulgaris","enrollment":64},{"nctId":"NCT00343187","phase":"PHASE2","title":"A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash","status":"TERMINATED","sponsor":"Allergan","startDate":"2006-06","conditions":"Rash, Non-small-Cell Lung Cancer","enrollment":2},{"nctId":"NCT00249782","phase":"PHASE2","title":"A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-11","conditions":"Rosacea","enrollment":400},{"nctId":"NCT00151541","phase":"PHASE3","title":"A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-02","conditions":"Acne Vulgaris","enrollment":301}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ACZONE Gel, 5%","genericName":"ACZONE Gel, 5%","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dapsone reduces inflammation and bacterial colonization in acne lesions through its antimicrobial and anti-inflammatory properties. Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}